METHODS: We conducted a systematic review to delineate the reported treatment details, safety, and efficacy of combining ICI and RT in patients with BC. PubMed, Embase, and Cochrane CENTRAL were searched between 2014 and 2023. Data were extracted to assess the details of ICIs/RT delivery, safety, and efficacy.
RESULTS: Of the 12 eligible studies, 9 involved patients with metastatic BC. Most studies were phase 1/2, had a small sample size (range, 8-28), and were heterogenous in patient population and reported outcomes. The combination was reported to be safe. We identified 1 study in the perioperative setting, which did a posthoc analysis of safety/efficacy of ICIs in the adjuvant setting with receipt and pattern of RT.
CONCLUSIONS: In conclusion, there are limited data on the dose, timing, fractionation, and volumes of RT in both the adjuvant and metastatic setting in BC. Ongoing/future trials should collect and report such data on RT details, whenever RT is used in combination with ICIs.
方法:我们进行了系统评价,以描述报告的治疗细节,联合ICI和RT治疗BC患者的安全性和有效性。Pubmed,Embase和CochraneCENTRAL在2014年至2023年之间进行了搜索。提取数据以评估ICI/RT交付的细节,安全性和有效性。
结果:在12项符合条件的研究中,9例涉及转移性BC患者。大多数研究为1/2期,样本量较小(范围8-28),在患者群体和报告的结果中具有异质性。据报道该组合是安全的。我们在围手术期确定了一项研究,在接受和RT模式的情况下,对ICIs在辅助治疗中的安全性/有效性进行了事后分析。
结论:结论:关于剂量的数据有限,定时,分馏,BC中辅助和转移设置中的RT体积。正在进行/未来的试验应收集和报告有关RT细节的数据,每当RT与ICI结合使用时。